Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
France
/
Pharmaceuticals & Biotech
/
Innate Pharma
IPH
Innate Pharma
Global Pricing Pressures Will Constrain Margins While Recovery Will Emerge
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
13 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€2.49
19.3% undervalued
intrinsic discount
16 Aug
€2.01
Loading
1Y
-4.7%
7D
0.9%
Author's Valuation
€2.5
19.3% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€2.5
19.3% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-63m
130m
2014
2017
2020
2023
2025
2026
2028
Revenue €32.0m
Earnings €2.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
21.90%
Biotech revenue growth rate
11.95%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.12%
Calculation
€2.52m
Earnings '28
x
160.60x
PE Ratio '28
=
€404.49m
Market Cap '28
€404.49m
Market Cap '28
/
135.97m
No. shares '28
=
€2.97
Share Price '28
€2.97
Share Price '28
Discounted to 2025 @ 6.11% p.a.
=
€2.49
Fair Value '25
